Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Millennium Partner in R&D and Supply Deal

SAN FRANCISCO, Oct. 24 – Millennium Pharmaceuticals entered a four-year R&D and volume discount supply agreement with Affymetrix, the companies announced Wednesday.

The deal includes co-development of gene expression array processes and applications for drug discovery and development, including next generation GeneChip technology applications.

Millennium, based in Cambridge, Mass., will transition its microarray use to Affymetrix’s GeneChip technology over the next year. Santa Clara-based Affymetrix will give Millennium preferred access and pricing to its gene expression platform, according to the companies.

Financial details of the agreement were not disclosed.

“Through this collaboration we will accelerate the evolution and use of our technology in drug development and health care,” said  Robert Lipshutz, vice president of corporate development and licensing at Affymetrix. “We plan to capture improvements to enhance our commercial offering.”

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.